by James Lyons-Weiler, PhD, Popular Rationalism, ©2025
(Dec. 20, 2025) — Washington, D.C. — December 2025
For decades, Americans suffering from persistent symptoms after Lyme disease treatment have heard the same refrains: “It’s all in your head.” “You’re cured.” “There is no such thing as chronic Lyme.”
That narrative is collapsing.
In a sweeping new federal initiative announced at the Department of Health and Human Services (HHS) Lyme Disease Roundtable on December 15, 2025, Secretary Robert F. Kennedy Jr. declared a fundamental shift in how the U.S. government views, funds, and responds to Lyme disease and its chronic sequelae.
HHS unveiled a dedicated federal Lyme disease hub (hhs.gov/lyme), renewed a $10 million public-private partnership to develop next-generation diagnostics, and published new CMS guidance formally recognizing Lyme-triggered chronic conditions as eligible for federally reimbursed chronic care management.
These moves represent the most significant federal reorientation toward Lyme disease since the CDC began tracking it in earnest in the 1990s, marking a pivotal break from decades of institutional minimization.
From Denial to Dedication: The Invisible Illness Gets a Name
The new HHS Lyme portal introduces a key concept: Lyme-IACCI—“Lyme infection-associated chronic conditions and illnesses.” This terminology deliberately sidesteps the decades-long scientific impasse over the phrase “chronic Lyme disease,” which some researchers continue to reject as diagnostically undefined or clinically unproven. By framing persistent post-treatment symptoms—including fatigue, joint pain, neurological dysfunction, and cognitive impairment—under the IACCI umbrella, HHS signals a formal shift in research and clinical focus.
The implications are large. “Gaslighting is over,” said one patient advocate quoted on the new hub. For the first time, the U.S. government officially acknowledges that a substantial subset of Lyme patients experiences persistent, often disabling symptoms despite having completed guideline-based antibiotic regimens.
Three federal actions stand out as immediate changes in approach:
- A New Federal Lyme Hub: HHS launched hhs.gov/lyme with a pledge of “radical transparency” and a roadmap for new resources, including a clinician locator, patient access tools, and open-data repositories expected in 2026. The portal situates Lyme within a broader “infection-associated chronic illness” framework—alongside Long COVID and vaccine injury—and presents the agency’s commitment to publish “Living Evidence Guidelines” on a six-month cycle.
- LymeX Renewed: The public-private LymeX partnership with the Steven & Alexandra Cohen Foundation will continue its diagnostics prize competition, aimed at delivering FDA-clearable assays capable of detecting active Borrelia infection. The $10 million initiative, launched in 2020 and now entering its fourth phase, reflects a federal diagnostic strategy long overdue.
- CMS Billing Clarification: A revised CMS webpage identifies Lyme disease as a legitimate infectious trigger for chronic care management billing. This guidance does not imply blanket treatment approval but does authorize care coordination, symptom monitoring, and personalized care planning under Medicare’s Chronic Care Management (CCM) rules.
Read the rest here.